Curaleaf Holdings (CURLF) Non-Current Deferred Tax Liability (2019 - 2025)
Curaleaf Holdings (CURLF) posted quarterly Non-Current Deferred Tax Liability of $212.0 million for Q4 2025, down 13.39% year-on-year from $244.8 million in Q4 2024, and down 13.39% on a QoQ basis from $244.8 million in Q4 2024.
Curaleaf Holdings (CURLF) Non-Current Deferred Tax Liability (2019 - 2025) Analysis & Trends
Curaleaf Holdings (CURLF) has reported Non-Current Deferred Tax Liability for 7 consecutive years, with $212.0 million the latest figure, recorded in Q4 2025.
- Quarterly Non-Current Deferred Tax Liability fell 13.39% year-over-year to $212.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $212.0 million (down 13.39% YoY) and the FY2025 annual result came in at $212.0 million, down 13.39% from the prior year.
- Non-Current Deferred Tax Liability retreated to $212.0 million in Q4 2025 per CURLF's latest filing, from $244.8 million in the prior quarter.
- Over the last five years, Non-Current Deferred Tax Liability for CURLF reached as high as $342.6 billion in Q1 2022 and fell as low as $212.0 million in Q4 2025.
- A 5-year average of $23.1 billion and a median of $303.5 million in 2021 frame the typical range for Non-Current Deferred Tax Liability.
- Annual changes were most pronounced in 2022 — Non-Current Deferred Tax Liability jumped 153837.26% — and 2024, when it declined 17.64%.
- Year by year, Non-Current Deferred Tax Liability stood at $257.8 million in 2021, then rose by 19.86% to $309.0 million in 2022, then fell by 3.82% to $297.2 million in 2023, then slipped by 17.64% to $244.8 million in 2024, then decreased by 13.39% to $212.0 million in 2025.
- According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $212.0 million, $244.8 million, and $276.2 million for Q4 2025, Q4 2024, and Q3 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Curaleaf Holdings | 7.13 Bn | 7.13 Bn | 157.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 212.00 Mn |
| Dec 31, 2025 | 212.00 Mn |
| Dec 31, 2024 | 244.77 Mn |
| Dec 31, 2024 | 244.77 Mn |
| Sep 30, 2024 | 276.22 Mn |
| Sep 30, 2024 | 276.22 Mn |
| Jun 30, 2024 | 285.59 Mn |
| Jun 30, 2024 | 285.59 Mn |
| Dec 31, 2023 | 297.19 Mn |
| Dec 31, 2023 | 297.19 Mn |
| Sep 30, 2023 | 311.04 Mn |
| Sep 30, 2023 | 311.04 Mn |
| Jun 30, 2023 | 318.21 Mn |
| Jun 30, 2023 | 318.21 Mn |
| Dec 31, 2022 | 308.97 Mn |
| Dec 31, 2022 | 308.97 Mn |
| Sep 30, 2022 | 332.31 Mn |
| Sep 30, 2022 | 332.31 Mn |
| Jun 30, 2022 | 334.81 Mn |
| Jun 30, 2022 | 334.81 Mn |